Fight Aging! Newsletter, October 11th 2021
In conclusion, this study examined how age and the process of aging are associated with changes in the microbiome of the small intestine, using validated sampling and processing techniques. The most significant differences are higher relative abundance of the phylum Proteobacteria and decreased relative abundance of Bacteroidetes in older subjects when compared to the youngest group. The higher relative abundance of Proteobacteria appeared to affect other duodenal microbial taxa, leading to decreased microbial diversity and increased relative abundance of coliforms and of anaerobic bacteria. The small intestine is vital to...
Source: Fight Aging! - October 10, 2021 Category: Research Authors: Reason Tags: Newsletters Source Type: blogs
Better Mapping Age-Related Changes in the Human Gut Microbiome
In conclusion, this study examined how age and the process of aging are associated with changes in the microbiome of the small intestine, using validated sampling and processing techniques. The most significant differences are higher relative abundance of the phylum Proteobacteria and decreased relative abundance of Bacteroidetes in older subjects when compared to the youngest group. The higher relative abundance of Proteobacteria appeared to affect other duodenal microbial taxa, leading to decreased microbial diversity and increased relative abundance of coliforms and of anaerobic bacteria. The small intestine is vital to...
Source: Fight Aging! - October 8, 2021 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Weight loss can help head off lasting damage caused by fatty liver
Non-alcoholic fatty liver disease is the most common cause of liver disease in the United States, and is estimated to affect up to a quarter of adults in the world. It is defined by excess fat accumulating in the liver and usually occurs in people with obesity, high blood sugars (diabetes), abnormal cholesterol or triglyceride levels, or high blood pressure. These disorders often run together and as a group are called metabolic syndrome. The “non-alcoholic” part of “non-alcoholic fatty liver disease” is important to distinguish it from alcohol-related liver disease, which can also cause excess liver fat.
How fat ca...
Source: Harvard Health Blog - April 30, 2020 Category: Consumer Health News Authors: Irun Bhan, MD Tags: Diet and Weight Loss Digestive Disorders Source Type: blogs
Incretin based drugs and gallbladder disease risk
(Source: Notes from Dr. RW)
Source: Notes from Dr. RW - December 22, 2016 Category: Internal Medicine Tags: endocrinology gastroenterology Source Type: blogs
Funtabulously Frivolous Friday Five 106
Just when you thought your brain could unwind on a Friday, you realise that it would rather be challenged with some good old fashioned medical trivia…introducing Funtabulously Frivolous Friday Five 106Question 1Which drug is derived from the saliva of the Gila Monster+ Reveal the Funtabulous Answerexpand(document.getElementById('ddet699757968'));expand(document.getElementById('ddetlink699757968'))ExenatideThe hormone exendin-4 occurs naturally in the saliva of the Gila monster, a large venomous lizard native to the southwestern United States and northwestern Mexico.Exenatide is a glucagon-like peptide-1 agonist (GLP-...
Source: Life in the Fast Lane - April 30, 2015 Category: Emergency Medicine Authors: Niall Hamilton Tags: Frivolous Friday Five LITFL FFFF Source Type: blogs
And if the Research Community Does in Fact Find a Viable Treatment for Obesity?
We report the discovery of a new monomeric peptide that reduces body weight and diabetic complications in rodent models of obesity by acting as an agonist at three key metabolically-related peptide hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors. Such balanced unimolecular triple agonism proved superior to any existing dual coagonists and best-in-class monoagonists to reduce body weight, enhance glycemic control and reverse hepatic steatosis in relevant rodent models. We demonstrate that these individual constituent activities harmonize to govern...
Source: Fight Aging! - December 11, 2014 Category: Research Authors: Reason Tags: Medicine, Biotech, Research Source Type: blogs
Doing Your Own Research
By David Spero
Doctors used to be the only source of medical information. Not anymore. You can get much of the same information on the Internet. Problem is, not all of the information you'll come across online is good. Here are some ways to empower yourself with good Internet research:
• It's good to have some general "search engine" sites as a starting point on your quest for information. I usually start with Google. Yahoo and Bing are also good. Search engine sites will give you a list of more specific sites where you can get the information you seek.
For example, a Google search for "diabetes" gives over 70 milli...
Source: Diabetes Self-Management - August 6, 2014 Category: Diabetes Authors: David Spero Source Type: blogs
Study Quantifies Whether Weight Loss Surgery Cures Diabetes
A study recently published in the Annals of Surgery gives much more insight into oft-repeated claims that weight loss surgery cures diabetes.The study can be found here:Can Diabetes Be Surgically Cured? Long-Term Metabolic Effects of Bariatric Surgery in Obese Patients with Type 2 Diabetes Mellitus. Brethauer, Stacy A. et al. Annals of Sugery, 10/13/2013. doi: 10.1097/SLA.0b013e3182a5034bThe study followed 217 people with Type 2 Diabetes who had had weight loss surgery for a period lasting between 5 and 9 years. One hundred and sixty-two had the radical Roux-en-Y gastric bypass operation, which irreversib...
Source: Diabetes Update - October 1, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Onlgyza Appears to Raise Risk of Heart Failure
A two year long study of two DPP-4 inhibitors (one not available in the U.S.) found that these drugs did not, as hoped, lower the risk of heart attack in people with diabetes who took them, and they found a surprising increase in cases of heart failure among people taking Onglyza.UPDATE 2-Doctors get good and bad safety news on diabetes drugshttp://www.reuters.com/article/2013/09/02/heart-diabetes-idUSL6N0GY0S720130902The study also claimed to find no sign of pancreatic disease with Onglyza, but there are several reasons to discount this finding:1. The study only lasted 2 years, which is far too short a time for the ...
Source: Diabetes Update - September 2, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Why Raise Your A1C?
According to this study from the University of California at San Francisco,
Achieving lower A1C levels with oral hypoglycemic medications was not associated with more frequent falls, except, among those using insulin, an A1C less than or equal to 6% increased risk of falls.
Below 6% is a pretty rare A1C for an older insulin-using adult.
A large study at Yale University found that
Contrary to conventional wisdom, hypoglycemia occurs just as frequently among those with poor glycemic control (higher A1C) as it does in those achieving near-normal glycemia.
And in the Action to Control Cardiovascular Risk in Diabetes (ACCORD...
Source: Diabetes Self-Management - August 28, 2013 Category: Diabetes Authors: David Spero Source Type: blogs
Berberine Works But May Very Well Be Harmful
I have been getting a lot of email of late about the supplement Berberine, which appears to be the latest miracle cure being sold to those people with diabetes who believe that completely unregulated herbs imported from countries with long histories of food and drug adulteration are somehow safer and "more natural" than the tightly regulated pharamceuticals.Berberine does appear to work to lower blood sugar. The problem is that we really know very little about how it does it or what its long term effects are on the body. I see many mentions on sites promoting berberine supplements of the fact that berberine has a lon...
Source: Diabetes Update - August 14, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Safety of Diabetes Drugs
Two studies published in professional journals this year have cast renewed doubt about the safety of one of our most important class of diabetes drugs. But the leading regulatory agencies both in Europe and the U.S. seem to think that those studies are flawed.
We call this class of drugs incretin-based or GLP-1 agonists. They include Byetta, Victoza, and Bydureon.
The most recent investigation of this class of drugs came out last month... (Source: David Mendosa's SharePosts)
Source: David Mendosa's SharePosts - August 12, 2013 Category: Diabetes Authors: David Mendosa Source Type: blogs
Final June Diabetes News Snippet Post
Jennysaid... The FDA is taking another look at Avandia's relationship to heart disease. http://www.forbes.com/sites/matthewherper/2013/06/04/battleground-fda-how-tomorrows-avandia-panel-could-help-shape-the-future-of-diabetes/But whatever they conclude about whether or not Avandia causes heart attacks, we know that it, like Actos, also weakens the bones over time and makes them prone to fracture, since it converts that stem cells that should become bone cells into baby fat cells.It, like Actos, also raises the chances of experiencing retinal edema--swelling in the blood vessels in your eye that can contribute to blindn...
Source: Diabetes Update - July 3, 2013 Category: Diabetes Authors: Jenny Source Type: blogs
Bright Minds and Complicated Problems – AACE 2013
Early last month I attended the American Association of Clinical Endocrinologists (AACE) Annual Meeting in Phoenix, AZ. It was a large event that brought those related to endocrinology together from around the world.
Going into the event I knew that a lot of the sessions were going to be over my head, and I knew that the event itself would be designed for doctors, not patients. But it was still a very informative event for me, and gave me a lot of great perspective.
Diabetes Technology
One of the first sessions I went to was about diabetes and technology. It was fascinating! One of the main takeaways I got from this sessio...
Source: Scott's Diabetes Blog - June 17, 2013 Category: Diabetes Authors: Scott K. Johnson Tags: Blog Posts Source Type: blogs
The ADA's " Investigation " of Incretin Drugs is a Gift to the Drug Companies
(Source: Diabetes Update)
Source: Diabetes Update - June 14, 2013 Category: Endocrinology Source Type: blogs
